Price
No data yet.
Social Signal Score
Revenue
$113.04M+71.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thomas A. McCourt
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 100
- Beta
- 0.21
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- -1.95
Financials
Revenue
$113.04M+71.0%Net Income
$51.29MEBITDA
$80.93MFree Cash Flow
$58.28MEPS (diluted)
$0.31Shares Outstanding (diluted)
165.45M+14.6%Operating Expenses
$33.73MCash & Debt
$79.13MReturn of Capital
$0.00Revenue by Segment (annual)
$298.22MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $296.15M | $24.02M | $0.15 |
| 2024 | $351.41M | $880.0K | $0.01 |
| 2023 | $442.74M | $-1.00B | $-6.45 |
| 2022 | $410.60M | $175.06M | $1.13 |
| 2021 | $413.75M | $528.45M | $3.26 |
| 2020 | $389.52M | $106.18M | $0.67 |
| 2019 | $428.41M | $21.50M | $0.38 |
| 2018 | $346.64M | $-282.37M | $-1.85 |
| 2017 | $298.28M | $-116.94M | $-0.79 |
| 2016 | $273.96M | $-81.71M | $-0.56 |
| 2015 | $149.56M | $-142.67M | $-1.00 |
| 2014 | $76.44M | $-189.62M | $-1.39 |
| 2013 | $22.88M | $-272.81M | $-2.35 |
| 2012 | $150.25M | $-72.62M | $-0.68 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.22
- Implied price
- $4.79
- Return from $4.30
- 2.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2.38 — -44.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| -2.0% | -13.0% | -10.0% | -7.3% | -4.9% | -2.7% |
| 3.0% | -8.6% | -5.4% | -2.6% | -0.1% | 2.2% |
| 8.0% | -4.2% | -0.8% | 2.1% | 4.8% | 7.2% |
| 13.0% | 0.3% | 3.8% | 6.9% | 9.6% | 12.2% |
| 18.0% | 4.7% | 8.4% | 11.6% | 14.5% | 17.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newsseekingalpha.com·4h ago·Positive
Ironwood Pharmaceuticals: High Dependence On Its Next Trial Ironwood Pharmaceuticals is a small-cap GI-focused biotech with strong LINZESS sales but looming patent expiry by 2029–2030. IRWD raised LINZESS full-year U.S. net sales guidance to $1.15–$1.2 billion and its own revenue forecast to $460–$485 million. Apraglutide, IRWD's pipeline asset for SBS-IF, showed statistically significant Phase 3 results and is key to future value.
View source ↗
Earnings
Mon, Nov 9(in 2 months)
Consensus estimate $0.30 per share
Typical surprise -3.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.31 vs $0.32miss
- Thu, May 7$0.24 vs $0.07beat
- Wed, Feb 25$-0.01 vs $0.02miss
- Mon, Nov 10$0.24 vs $0.09beat
- Thu, Aug 7$0.14 vs $-0.02beat
- Wed, May 7$-0.23 vs $-0.05miss
Estimates and results for IRWD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IRWD officers and directors.
- Bought
- —
- Sold
- $24.7m
0 trades
40 trades
- Silver Ronaldsold
- Mchugh Juliesold
- Denner Alexander Jsold
- Denner Alexander Jsold
- John Minardosold
- Shetzline Michaelsold
- Gaskins Tammi Lsold
- Mccourt Thomas Asold
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.